风湿病学中补体治疗格局的演变
本文综述补体系统在多种风湿病中的致病作用及治疗进展,重点总结抗中性粒细胞胞浆抗体相关血管炎(AAV)和类风湿关节炎(RA)的转化研究与临床试验,指出补体替代途径生成C5a是靶器官损伤的主要驱动因素,AAV中C5aR1拮抗剂显示显著减少糖皮质激素用量的效果,而RA中C5/C5aR1抑制剂仅显示 modest 获益。
要点
- 补体替代途径生成C5a是AAV和RA靶器官损伤的主要驱动因素。
- AAV中口服C5aR1拮抗剂试验显示显著减少糖皮质激素用量并初步临床获益。
- RA中C5和C5aR1抑制剂仅显示 modest 获益,需探索不同靶点或干预时机。
核心结论
- 补体通路的不适当激活介导许多人类疾病的组织炎症和损伤,包括风湿科关注的关键疾病。
研究设计与样本
- 综述总结聚焦于AAV和RA的补体相关发病机制与临床试验的出版物,以及其他疾病相关研究。
主要发现
- 转化研究显示AAV和RA患者受累组织和血液中补体激活,小鼠模型提示补体替代途径生成C5a是靶器官损伤的主要驱动因素。
- AAV中新型小分子口服C5a过敏毒素受体(C5aR1)拮抗剂临床试验显示显著减少糖皮质激素用量并初步临床获益。
- RA中尽管生物标志物和小鼠模型研究强力支持,但C5和C5aR1抑制剂干预仅显示 modest 获益。
临床怎么用
- 在AAV中可考虑C5aR1拮抗剂以减少糖皮质激素用量,但需进一步验证临床获益。
- RA中C5/C5aR1抑制剂证据有限,不建议常规使用,需探索不同靶点或干预时机。
局限性
- 原文未报告综述的检索范围、纳入标准或偏倚评估方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The pathogenic roles of the complement system in many human diseases have become increasingly understood, in large part through the results of informative clinical trials. In addition, based on biomarker studies in patients and results of murine models, there are an increasing number of indications under consideration for the use of therapeutics targeting different components of the pathway. Here, lessons learned from several of these studies are reviewed, with an emphasis on diseases of clinical and research interest to rheumatologists. METHODS: Publications focused on the complement-related pathogenesis and clinical trials of antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and rheumatoid arthritis (RA), in addition to studies relevant to other diseases, are summarised. RESULTS: Following translational studies demonstrating activation in affected tissues and blood from patients, the potential pathogenic roles of complement in AAV and RA were studied in murine models. These studies suggested in both diseases that complement alternative pathway generation of C5a is a primary driver of target organ damage. In AAV, clinical trials using a novel small molecular oral C5a anaphylatoxin receptor (C5aR1) antagonist revealed a substantial corticosteroid-sparing effect and initial evidence of clinical benefit. With regard to RA, although there is strong support through biomarker and murine model studies, intervention with C5 and C5aR1 inhibitors revealed only modest benefit, and additional work is necessary to determine if different targets or timing of intervention is necessary. Beyond AAV and RA, a substantial number of additional diseases cared for by rheumatologists exhibit evidence of complement activation in a potentially pathogenic manner. CONCLUSIONS: Inappropriate activation of the complement pathway mediates tissue inflammation and damage in many human diseases, including key ones cared for by rheumatologists.
引用
- Holers VM. The evolving landscape of complement therapeutics in rheumatology. Ann Rheum Dis. 2026. PMID: 42002469. doi:10.1016/j.ard.2026.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。